CODX — Co-Diagnostics Cashflow Statement
0.000.00%
Last trade - 00:00- $11.75m
- -$18.00m
- $3.92m
- 47
- 48
- 19
- 31
Annual cashflow statement for Co-Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 42.5 | 36.7 | -14.2 | -35.3 | -37.6 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.91 | 6.05 | 18 | 8.8 | 4.35 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -16.8 | -2.9 | 6.37 | 5.64 | 2.75 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 28.2 | 41.1 | 6.57 | -22.1 | -29.2 |
| Capital Expenditures | -0.774 | -0.669 | -1.43 | -1.37 | -0.748 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -5.05 | 4.77 | -56.7 | 16.8 | 17.8 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -5.82 | 4.1 | -58.2 | 15.4 | 17.1 |
| Financing Cash Flow Items | -1.46 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 19.7 | 0.45 | -14 | -1.36 | 0.104 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 42.1 | 45.6 | -65.6 | -8.06 | -12 |